These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 11674923)
61. Impact of allergic rhinitis treatment on quality of life. Tripathi A; Patterson R Pharmacoeconomics; 2001; 19(9):891-9. PubMed ID: 11700776 [TBL] [Abstract][Full Text] [Related]
62. Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine. Frèche C; Leynadier F; Horak F; Hide D; Gracia FD; Goos M; Bachert C; Horvath A; Antosova E; Verrecchia M; Soussen PB Ann Allergy Asthma Immunol; 2002 Sep; 89(3):304-10. PubMed ID: 12269652 [TBL] [Abstract][Full Text] [Related]
63. Montelukast decreased exhaled nitric oxide in children with perennial allergic rhinitis. Hung CH; Hua YM; Hsu WT; Lai YS; Yang KD; Jong YJ; Chu YT Pediatr Int; 2007 Jun; 49(3):322-7. PubMed ID: 17532829 [TBL] [Abstract][Full Text] [Related]
64. [Validation of the Spanish version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)]. Soler R; de la Hoz B; Badia X; Mercadal J; Lozano R; Benavides A; Roset M; Rev Clin Esp; 2004 Mar; 204(3):131-8. PubMed ID: 15025979 [TBL] [Abstract][Full Text] [Related]
65. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Crampton HJ Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545 [TBL] [Abstract][Full Text] [Related]
66. Double-blind study of cetirizine and loratadine versus placebo in patients with allergic rhinitis. Nunes C; Ladeira S J Investig Allergol Clin Immunol; 2000; 10(1):20-3. PubMed ID: 10780795 [TBL] [Abstract][Full Text] [Related]
67. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. Bousquet J; Duchateau J; Pignat JC; Fayol C; Marquis P; Mariz S; Ware JE; Valentin B; Burtin B J Allergy Clin Immunol; 1996 Aug; 98(2):309-16. PubMed ID: 8757208 [TBL] [Abstract][Full Text] [Related]
68. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Van Cauwenberge P; Juniper EF Clin Exp Allergy; 2000 Jun; 30(6):891-9. PubMed ID: 10848909 [TBL] [Abstract][Full Text] [Related]
69. Generic or disease-specific quality of life scales to characterize health status in allergic rhinitis? Kremer B; Klimek L; Bullinger M; Mösges R Allergy; 2001 Oct; 56(10):957-63. PubMed ID: 11576074 [TBL] [Abstract][Full Text] [Related]
70. Treatment of chronic rhinitis by an allergy specialist improves quality of life outcomes. Bagenstose SE; Bernstein JA Ann Allergy Asthma Immunol; 1999 Dec; 83(6 Pt 1):524-8. PubMed ID: 10619343 [TBL] [Abstract][Full Text] [Related]
71. Fluticasone furoate nasal spray is effective and well tolerated for perennial allergic rhinitis in adolescents and adults. Given JT; Cheema AS; Dreykluft T; Stillerman A; Silvey M; Wu W; Snowise NG; Philpot E Am J Rhinol Allergy; 2010; 24(6):444-50. PubMed ID: 21144223 [TBL] [Abstract][Full Text] [Related]
72. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Juniper EF; Thompson AK; Ferrie PJ; Roberts JN Clin Exp Allergy; 2000 Jan; 30(1):132-40. PubMed ID: 10606940 [TBL] [Abstract][Full Text] [Related]
73. Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo. Hampel FC; Ratner PH; Amar NJ; van Bavel JH; Mohar D; Fairchild CJ; Wall GM; Brubaker MJ; Drake M; Crenshaw KM Allergy Asthma Proc; 2006; 27(3):202-7. PubMed ID: 16913262 [TBL] [Abstract][Full Text] [Related]
74. [The place of new antihistamines in allergy management. Apropos of desloratadine]. Sabbah A Allerg Immunol (Paris); 2002 Dec; 34(10):377-83. PubMed ID: 12575624 [TBL] [Abstract][Full Text] [Related]
75. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Lanier BQ; Gross RD; Marks BB; Cockrum PC; Juniper EF Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736 [TBL] [Abstract][Full Text] [Related]
76. Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Walter Canonica G; Bousquet J; Van Hammée G; Bachert C; Durham SR; Klimek L; Mullol J; Van Cauwenberge PB; Respir Med; 2006 Oct; 100(10):1706-15. PubMed ID: 16723217 [TBL] [Abstract][Full Text] [Related]
77. Bilastine and quality of life. Jáuregui I; Bartra J; del Cuvillo A; Dávila I; Ferrer M; Montoro J; Mullol J; Sastre J; Valero A J Investig Allergol Clin Immunol; 2011; 21 Suppl 3():16-23. PubMed ID: 22185046 [TBL] [Abstract][Full Text] [Related]
78. Why generic and disease-specific quality-of-life instruments should be used together for the evaluation of patients with persistent allergic rhinitis. Leong KP; Yeak SC; Saurajen AS; Mok PK; Earnest A; Siow JK; Chee NW; Yeo SB; Khoo ML; Lee JC; Seshadri R; Chan SP; Tang CY; Chng HH Clin Exp Allergy; 2005 Mar; 35(3):288-98. PubMed ID: 15784105 [TBL] [Abstract][Full Text] [Related]
79. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. Bousquet J; Bullinger M; Fayol C; Marquis P; Valentin B; Burtin B J Allergy Clin Immunol; 1994 Aug; 94(2 Pt 1):182-8. PubMed ID: 8064070 [TBL] [Abstract][Full Text] [Related]
80. Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine. Ciebiada M; Ciebiada MG; Kmiecik T; DuBuske LM; Gorski P J Investig Allergol Clin Immunol; 2008; 18(5):343-9. PubMed ID: 18973097 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]